Free Trial

Neurogene (NGNE) Competitors

Neurogene logo
$17.28 -0.76 (-4.21%)
As of 10:38 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

NGNE vs. PAHC, MLYS, COLL, SNDX, RCUS, ELVN, AVDL, SYRE, NTLA, and PHVS

Should you be buying Neurogene stock or one of its competitors? The main competitors of Neurogene include Phibro Animal Health (PAHC), Mineralys Therapeutics (MLYS), Collegium Pharmaceutical (COLL), Syndax Pharmaceuticals (SNDX), Arcus Biosciences (RCUS), Enliven Therapeutics (ELVN), Avadel Pharmaceuticals (AVDL), Spyre Therapeutics (SYRE), Intellia Therapeutics (NTLA), and Pharvaris (PHVS). These companies are all part of the "pharmaceutical products" industry.

Neurogene vs.

Phibro Animal Health (NASDAQ:PAHC) and Neurogene (NASDAQ:NGNE) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, community ranking, profitability, valuation, media sentiment, analyst recommendations, earnings, risk and institutional ownership.

Phibro Animal Health presently has a consensus target price of $20.00, indicating a potential downside of 13.12%. Neurogene has a consensus target price of $44.60, indicating a potential upside of 147.23%. Given Neurogene's stronger consensus rating and higher probable upside, analysts plainly believe Neurogene is more favorable than Phibro Animal Health.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Phibro Animal Health
2 Sell rating(s)
2 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.50
Neurogene
0 Sell rating(s)
2 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.71

99.3% of Phibro Animal Health shares are owned by institutional investors. Comparatively, 52.4% of Neurogene shares are owned by institutional investors. 50.1% of Phibro Animal Health shares are owned by company insiders. Comparatively, 9.9% of Neurogene shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Neurogene had 12 more articles in the media than Phibro Animal Health. MarketBeat recorded 19 mentions for Neurogene and 7 mentions for Phibro Animal Health. Phibro Animal Health's average media sentiment score of 1.57 beat Neurogene's score of 0.34 indicating that Phibro Animal Health is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Phibro Animal Health
5 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive
Neurogene
8 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
3 Negative mention(s)
0 Very Negative mention(s)
Neutral

Phibro Animal Health received 286 more outperform votes than Neurogene when rated by MarketBeat users. However, 88.57% of users gave Neurogene an outperform vote while only 59.81% of users gave Phibro Animal Health an outperform vote.

CompanyUnderperformOutperform
Phibro Animal HealthOutperform Votes
317
59.81%
Underperform Votes
213
40.19%
NeurogeneOutperform Votes
31
88.57%
Underperform Votes
4
11.43%

Phibro Animal Health has a beta of 0.62, indicating that its stock price is 38% less volatile than the S&P 500. Comparatively, Neurogene has a beta of 1.56, indicating that its stock price is 56% more volatile than the S&P 500.

Phibro Animal Health has higher revenue and earnings than Neurogene. Neurogene is trading at a lower price-to-earnings ratio than Phibro Animal Health, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Phibro Animal Health$1.19B0.78$2.42M$0.7829.51
Neurogene$925K278.15-$36.32M-$4.35-4.15

Phibro Animal Health has a net margin of 1.75% compared to Neurogene's net margin of 0.00%. Phibro Animal Health's return on equity of 25.35% beat Neurogene's return on equity.

Company Net Margins Return on Equity Return on Assets
Phibro Animal Health1.75% 25.35% 6.21%
Neurogene N/A -32.81%-27.96%

Summary

Phibro Animal Health beats Neurogene on 11 of the 18 factors compared between the two stocks.

Get Neurogene News Delivered to You Automatically

Sign up to receive the latest news and ratings for NGNE and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

NGNE vs. The Competition

MetricNeurogenePharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$257.29M$6.47B$5.33B$8.39B
Dividend YieldN/A2.64%5.21%4.11%
P/E Ratio-4.159.0626.7119.71
Price / Sales278.15251.50386.46120.65
Price / CashN/A65.8538.2534.62
Price / Book1.246.456.774.50
Net Income-$36.32M$143.98M$3.23B$248.22M
7 Day Performance0.28%0.38%0.48%-0.78%
1 Month Performance16.84%2.14%9.10%11.53%
1 Year Performance-42.71%-0.33%18.56%8.99%

Neurogene Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NGNE
Neurogene
2.3473 of 5 stars
$17.28
-4.2%
$44.60
+158.1%
-44.3%$246.73M$925,000.00-3.9890Analyst Forecast
Gap Up
PAHC
Phibro Animal Health
3.5213 of 5 stars
$24.50
+9.0%
$20.00
-18.4%
+25.0%$992.32M$1.11B51.041,860News Coverage
Positive News
Analyst Revision
MLYS
Mineralys Therapeutics
2.8785 of 5 stars
$15.01
+2.5%
$33.00
+119.9%
+30.4%$973.79MN/A-4.1228Analyst Upgrade
Gap Down
COLL
Collegium Pharmaceutical
4.0401 of 5 stars
$29.56
+2.3%
$43.80
+48.2%
-15.7%$949.82M$631.45M12.74210Gap Up
SNDX
Syndax Pharmaceuticals
3.8241 of 5 stars
$10.99
+2.7%
$35.91
+226.7%
-47.9%$945.66M$43.72M-3.03110Positive News
RCUS
Arcus Biosciences
3.5369 of 5 stars
$8.82
+6.5%
$25.67
+191.2%
-47.6%$933.38M$141M-2.80500Positive News
High Trading Volume
ELVN
Enliven Therapeutics
2.4752 of 5 stars
$19.01
+3.2%
$40.33
+112.2%
-26.7%$932.75MN/A-10.0150
AVDL
Avadel Pharmaceuticals
2.0783 of 5 stars
$9.59
+2.1%
$19.43
+102.6%
-43.9%$926.67M$169.12M-12.1470Positive News
SYRE
Spyre Therapeutics
2.3252 of 5 stars
$14.93
+5.9%
$51.17
+242.7%
-57.6%$899.92M$890,000.00-2.00100Positive News
NTLA
Intellia Therapeutics
4.6413 of 5 stars
$8.55
+5.3%
$36.90
+331.6%
-63.6%$885.64M$57.88M-1.57600Positive News
Analyst Forecast
PHVS
Pharvaris
1.2605 of 5 stars
$16.81
-1.1%
$41.67
+147.9%
-17.9%$879.00MN/A-6.0030

Related Companies and Tools


This page (NASDAQ:NGNE) was last updated on 5/23/2025 by MarketBeat.com Staff
From Our Partners